Memphasys Ltd (AU:MEM) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Memphasys Limited reports robust progress with its Felix™ System, achieving repeat sales and successful live births in Japan and India, and securing exclusive distribution agreements in key markets like Japan, Canada, and New Zealand. The company is also conducting a clinical trial expected to conclude by year’s end, with regulatory submissions to follow. Moreover, Memphasys is developing an Oxidative Stress measurement system, further expanding its assisted reproductive technology offerings.
For further insights into AU:MEM stock, check out TipRanks’ Stock Analysis page.